What does Actavis get in $66bn Allergan buy?
This article was originally published in Scrip
When Actavis closes its $66bn acquisition of Allergan, the generic drug specialist and growing brand-name medicine marketer will grow in international markets and strengthen or add products in certain disease areas (scripintelligence.com, 18 November 2014).
You may also be interested in...
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Pfizer’s CEO will likely shed more light on the company’s on-off-on attitude towards its consumer health business, while Allergan will certainly have a lot of explaining to do regarding its Restasis patent protection strategy. Sanofi, Teva and AstraZeneca are also scheduled to report Q3 results in the coming days. Scrip outlines the key issues to watch for.
Allergan generated enough cash flow in the first quarter to justify increased spending to develop and promote new products in 2017 – reinvesting because it can, not necessarily because it has to.